Virologic parameters at baseline and 12 months after rituximab treatment
| . | Start . | End . | ||||
|---|---|---|---|---|---|---|
| . | Serum . | Supernatant . | Cryoprecipitate . | Serum . | Supernatant . | Cryoprecipitate . |
| Responders (n = 16) | ||||||
| HCV RNA, IU/mL | 477 231 ± 323 144 | 170 216 ± 141 228 | 2 846 136 ± 2 476 2524-150 | 765 667 ± 261 058 | 374 628 ± 367 060 | 4 041 559 ± 3 564 3274-150 |
| Anti-HCV antibody titer, sample/cutoff ratio | 91.0 ± 30.0 | 64.5 ± 42.5 | 21.3 ± 17.54-150 | 65.8 ± 41.58 | 56.7 ± 38.6 | 5.3 ± 3.54-150 |
| Nonresponders (n = 4) | ||||||
| HCV RNA, IU/mL | 452 667 ± 365 761 | 560 233 ± 776 427 | 3 039 259 ± 4 029 6984-150 | 456 333 ± 345 104 | 451 873 ± 249 449 | 2 881 900 ± 3 900 952 |
| Anti-HCV antibody titer, sample/cutoff ratio | 83.6 ± 34.3 | 52.6 ± 44.6 | 21.0 ± 24.14-150 | 73.07 ± 53.63 | 47.5 ± 40.0 | 26.4 ± 17.7 |
| . | Start . | End . | ||||
|---|---|---|---|---|---|---|
| . | Serum . | Supernatant . | Cryoprecipitate . | Serum . | Supernatant . | Cryoprecipitate . |
| Responders (n = 16) | ||||||
| HCV RNA, IU/mL | 477 231 ± 323 144 | 170 216 ± 141 228 | 2 846 136 ± 2 476 2524-150 | 765 667 ± 261 058 | 374 628 ± 367 060 | 4 041 559 ± 3 564 3274-150 |
| Anti-HCV antibody titer, sample/cutoff ratio | 91.0 ± 30.0 | 64.5 ± 42.5 | 21.3 ± 17.54-150 | 65.8 ± 41.58 | 56.7 ± 38.6 | 5.3 ± 3.54-150 |
| Nonresponders (n = 4) | ||||||
| HCV RNA, IU/mL | 452 667 ± 365 761 | 560 233 ± 776 427 | 3 039 259 ± 4 029 6984-150 | 456 333 ± 345 104 | 451 873 ± 249 449 | 2 881 900 ± 3 900 952 |
| Anti-HCV antibody titer, sample/cutoff ratio | 83.6 ± 34.3 | 52.6 ± 44.6 | 21.0 ± 24.14-150 | 73.07 ± 53.63 | 47.5 ± 40.0 | 26.4 ± 17.7 |
Statistically significant.